{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:06:17Z","timestamp":1789621577034,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["UL1 TR000073"],"award-info":[{"award-number":["UL1 TR000073"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.clml.2016.09.002","type":"journal-article","created":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T18:45:38Z","timestamp":1474137938000},"page":"684-692.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0714-734X","authenticated-orcid":false,"given":"Aaron S.","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Ruthazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.09.002_bib1","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"343","article-title":"Post-transplant lymphoproliferative disorders","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.clml.2016.09.002_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1634\/theoncologist.11-6-674","article-title":"Post-transplant lymphoproliferative disorders","volume":"11","author":"LaCasce","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2016.09.002_bib3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1053\/j.ajkd.2011.07.015","article-title":"Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses","volume":"58","author":"Kasiske","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clml.2016.09.002_bib4","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","article-title":"Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry","volume":"6","author":"Caillard","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2016.09.002_bib5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2016.09.002_bib6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2141.2010.08161.x","article-title":"Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients\u2014BCSH and BTS guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.09.002_bib7","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2000.18.21.3622","article-title":"Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center","volume":"18","author":"Mamzer-Bruneel","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.09.002_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1600-6143.2005.01211.x","article-title":"Treatment of PTLD with rituximab or chemotherapy","volume":"6","author":"Elstrom","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2016.09.002_bib9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.10595","article-title":"CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation","volume":"92","author":"Choquet","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.09.002_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2016.09.002_bib11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","article-title":"Multicenter analysis of 80 solid organ\u00a0transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era","volume":"28","author":"Evens","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.09.002_bib12","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2008.20.0857","article-title":"Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center","volume":"27","author":"Knight","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.09.002_bib13","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/ajt.12234","article-title":"Plasma cell neoplasms in US solid organ transplant recipients","volume":"13","author":"Engels","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2016.09.002_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2016.09.002_bib15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1055-9965.EPI-09-1220","article-title":"Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients","volume":"19","author":"Quinlan","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clml.2016.09.002_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","article-title":"Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas","volume":"12","author":"Caillard","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2016.09.002_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/tri.12091","article-title":"Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients","volume":"26","author":"Karuturi","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.clml.2016.09.002_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2010.039214","article-title":"Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases","volume":"96","author":"Trappe","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.09.002_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1309\/AJCPX70TIHETNBRL","article-title":"Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: clinical and pathologic features","volume":"132","author":"Richendollar","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2016.09.002_bib20","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2012-06-438549","article-title":"Early onset, EBV(\u2212) PTLD in pediatric liver-small bowel transplantation recipients: a spectrum of plasma cell neoplasms with favorable prognosis","volume":"121","author":"Perry","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.09.002_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/modpathol.3800080","article-title":"Post-transplant plasma cell myeloma and polymorphic lymphoproliferative disorder with monoclonal serum protein occurring in solid organ transplant recipients","volume":"17","author":"Sun","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2016.09.002_bib22","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1200\/JCO.2011.39.5855","article-title":"Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature","volume":"30","author":"Wang","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.09.002_bib23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.tp.0000203554.54242.56","article-title":"Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis","volume":"81","author":"Caillard","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2016.09.002_bib24","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.09.002_bib25","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2012.46.3323","article-title":"Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States","volume":"31","author":"Warren","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.09.002_bib26","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2008-01-132167","article-title":"Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder","volume":"111","author":"Portell","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2016.09.002_bib27","first-page":"5","article-title":"OPTN\/SRTR 2012 annual data report","volume":"14","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2016.09.002_bib28","unstructured":"Surveillance, Epidemiology, and End Results. SEER research data, 2000-2010. ASCII text data. Available at: http:\/\/seer.cancer.gov\/data\/. Accessed: April 29, 2013."},{"key":"10.1016\/j.clml.2016.09.002_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"JASA"},{"key":"10.1016\/j.clml.2016.09.002_bib30","series-title":"Clinical Prediction Models","author":"Steyerberg","year":"2009"},{"key":"10.1016\/j.clml.2016.09.002_bib31","series-title":"R: A Language and Environment for Statistical Computing","author":"Foundation","year":"2013"},{"key":"10.1016\/j.clml.2016.09.002_bib32","unstructured":"RStudio. Integrated development environment for R. Available at: http:\/\/www.rstudio.org\/. Accessed: February 4, 2013."},{"key":"10.1016\/j.clml.2016.09.002_bib33","series-title":"Table\u00a01.10: Transplant Recipient Characteristics, 2002 to 2011","year":"2014"},{"key":"10.1016\/j.clml.2016.09.002_bib34","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.09.002_bib35","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1111\/j.1600-6143.2012.04126.x","article-title":"Bortezomib for acute antibody-mediated rejection in liver transplantation","volume":"12","author":"Paterno","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2016.09.002_bib36","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/TP.0b013e3181fdd9b0","article-title":"The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation","volume":"90","author":"Flechner","year":"2010","journal-title":"Transplantation"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016305584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016305584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:46Z","timestamp":1761870466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016305584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S2152265016305584"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.09.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}